Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

In this multicenter, randomized, double-blind, placebo-controlled trial in patients with coronary heart disease,240 eligible patients aged ≥18 years will be randomized to receive placebo or Xuesaitong Soft Capsules(1.32g/d) and be followed up for 3 months. The primary endpoint of this study is hsCRP change from baseline to 3 months. The secondary endpoint is the changes of following indicators or scores from baseline to 3 months:(Ⅰ)other inflammation indicators except for hsCRP. (Ⅱ) inhibition of platelet aggregation; (Ⅲ)endothelial function indicators; (Ⅳ)blood lipid levels; (Ⅴ) seattle angina questionnaire score; (Ⅵ)36-item short form health survey score. The safety of using Xuesaitong soft capsules in patients with coronary heart disease will also be evaluated. The generalized linear mixed effects model will be used to evaluate the efficacy endpoint for the "full analysis set". For the safety analysis set, Chi-square test will be used to evaluate the safety endpoint.

Inclusion criteria

• Age ≥18 years old
• Chronic coronary artery disease: meet any of the following conditions, and the condition is stable for at least 3 months:

• History of myocardial infarction
• Have received coronary interventional therapy
• There are symptoms of myocardial ischemia (such as chest pain) and objective evidence (stress electrocardiogram or stress myocardial perfusion imaging indicated myocardial ischemia or coronary artery stenosis ≥50% )
• High-sensitivity C-reactive protein ≥2mg/L
• Currently taking moderate or above intensity statins lipid-lowering drugs
• Currently taking antiplatelet drugs
• Sign informed consent

Exclusion criteria

• Patients fulfilling any of the following criteria are not eligible for inclusion in this trial:

• Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months
• Previously received coronary artery bypass grafting
• Stroke occurred within the previous 3 months
• Symptomatic heart failure (HF) in the past, or documented left ventricular ejection fraction < 35%
• Revascularization or surgical procedures are planned within the next 3 months
• Progressive neuromuscular disease, or creatine kinase (CK) levels > 3 times the normal upper limit (ULN)
• Lupus, inflammatory bowel disease, severe arthritis and other inflammatory diseases
• Immunosuppressants such as cyclosporine, tacrolimus, azathioprine, or systemic steroids are currently being taken or planned during the study
• History of hereditary dyslipidemia such as familial hypercholesterolemia
• There has been a change in lipid regulation treatment within the past 1 month, or there is a current adjustment plan
• History of symptomatic non-traumatic cerebral hemorrhage at any time in the past
• History of gastrointestinal bleeding or major surgery within the past 6 months
• Use of Xuesaitong soft capsules or preparations containing the main ingredients of Xuesaitong in the past 1 month
• There were clear adverse reactions to the main components of Xuesaitong in the past
• Active liver disease, or alanine aminotransferase (ALT) levels > 3 times the upper limit of normal (ULN)
• Chronic kidney disease, or estimated glomerular filtration rate (eGFR) <60ml/ (min×1.73m2)
• Pregnancy or planned pregnancy, or breastfeeding
• Malignant tumors, or other serious diseases with an estimated survival of less than 1 year
• Mental disorders or communication disorders, cognitive impairment, or other serious medical conditions that may affect study participation
• Have participated in or are participating in other clinical trials within the last 1 month
• Poor adherence to follow-up or medication is known